AQR Capital Management
VTGN icon

AQR Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

AQR Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-346
Closed -$1.07K – 2263
2022
Q4 		$1.07K Buy
+346
New +$1.3K ﹤0.01% 2192
2022
Q2 		– Sell
-662
Closed -$25K – 2306
2022
Q1 		$25K Sell
662
-2,558
-79% -$112K ﹤0.01% 2199
2021
Q4 		$188K Sell
3,220
-2,828
-47% -$184K ﹤0.01% 2098
2021
Q3 		$497K Buy
6,048
+2,391
+65% +$208K ﹤0.01% 1867
2021
Q2 		$346K Buy
+3,657
New +$271K ﹤0.01% 2008

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AQR Capital Management's VTGN Position: Q1 2023 in Review

AQR Capital Management sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 346 shares — an estimated $1.07K sold.

AQR Capital Management first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $497K in Q3 2021. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • AQR Capital Management reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • AQR Capital Management sold 346 VistaGen Therapeutics shares in Q1 2023, an estimated $1.07K.
  • AQR Capital Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • AQR Capital Management's VistaGen Therapeutics position peaked at $497K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on AQR Capital Management's 13F filing for Q1 2023, filed 15 May 2023.